CORDUA, ALESSIA
 Distribuzione geografica
Continente #
EU - Europa 104
NA - Nord America 65
AS - Asia 57
SA - Sud America 26
AF - Africa 1
Totale 253
Nazione #
IT - Italia 66
US - Stati Uniti d'America 62
SG - Singapore 28
BR - Brasile 22
DE - Germania 13
CN - Cina 9
VN - Vietnam 8
FI - Finlandia 7
NL - Olanda 7
IN - India 6
CO - Colombia 3
GB - Regno Unito 3
AT - Austria 2
RU - Federazione Russa 2
AR - Argentina 1
BD - Bangladesh 1
CA - Canada 1
CH - Svizzera 1
CZ - Repubblica Ceca 1
FR - Francia 1
ID - Indonesia 1
IQ - Iraq 1
IR - Iran 1
LB - Libano 1
MX - Messico 1
SE - Svezia 1
TR - Turchia 1
TT - Trinidad e Tobago 1
ZA - Sudafrica 1
Totale 253
Città #
Carbonia 12
Munich 12
Singapore 10
Dallas 9
Chicago 7
Chandler 6
Ho Chi Minh City 6
Rome 6
Turku 6
Ashburn 5
Bengaluru 4
Ercolano 4
Hefei 4
London 3
Paola 3
Afragola 2
Delhi 2
Gesuiti 2
Reggio Calabria 2
San Nicola Manfredi 2
Santa Clara 2
São Paulo 2
Alvorada 1
Balıkesir 1
Baturité 1
Beijing 1
Beirut 1
Benevento 1
Biên Hòa 1
Bragança Paulista 1
Brasília 1
Brooklyn 1
Caicó 1
Chaguanas 1
Charlotte 1
Cleveland 1
Cosenza 1
Crestview 1
Dolores Hidalgo 1
Hanoi 1
Helsinki 1
Indian Trail 1
Isidro Casanova 1
Jacarezinho 1
Johannesburg 1
Lajeado 1
Lawrence 1
Los Angeles 1
Manaus 1
Medellín 1
Mocoa 1
Mosul 1
Naples 1
Niterói 1
Norwich 1
Nova Iguaçu 1
Nuremberg 1
Olomouc 1
Osasco 1
Padang 1
Palermo 1
Petrópolis 1
Pittsburgh 1
Ponto Belo 1
Porto Alegre 1
Princeton 1
Salt Lake City 1
Salvador 1
Satuba 1
St Petersburg 1
Stockholm 1
Taubaté 1
Torres 1
Ubá 1
Vienna 1
Votuporanga 1
Zipaquirá 1
Totale 166
Nome #
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 95
miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review 78
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 61
A systematic review of non-coding RNA therapeutics in early clinical trials: a new perspective against cancer 29
Totale 263
Categoria #
all - tutte 1.421
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.421


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202214 0 0 0 0 0 0 0 0 9 5 0 0
2022/202318 2 1 1 0 4 3 0 1 2 3 1 0
2023/202432 15 3 4 1 1 3 0 0 0 0 3 2
2024/2025118 5 2 1 4 6 16 8 3 7 2 32 32
2025/202681 9 15 20 19 18 0 0 0 0 0 0 0
Totale 263